title: Clindamycin pharmacokinetics and tissue penetration after head and neck surgery.
abstract: Penetration of clindamycin into surgical wounds was studied in 10 patients undergoing radical head and neck surgery. Patients received one preoperative and three postoperative intravenous doses of clindamycin 600 mg. During surgery, samples of plasma and sternocleidomastoid muscle were obtained. Additional plasma samples were collected just before the fourth dose of clindamycin, just after that dose was infused, and 1, 2, 4, 6, 8, and 12 hours after dosing. Samples of wound exudate were collected at 2, 4, 6, 8, and 12 hours after the fourth dose. The muscle, plasma, and wound exudate samples were assayed for clindamycin base by a gas-liquid chromatographic method. Plasma and wound exudate samples obtained during surgery and one and eight hours after the fourth dose were assayed by a radial immunodiffusion technique for content of alpha 1-acid glycoprotein (AAG), the major binding protein for clindamycin. Pharmacokinetic values for plasma and wound drainage were calculated and compared. Concentrations of clindamycin in muscle (three to six hours after the first dose) ranged from 0.6 to 5.1 micrograms/g; the ratio of tissue to plasma concentrations ranged from 0.24 to 0.82. The highest mean clindamycin concentration in wound drainage was 4.9 micrograms/mL after the fourth dose, approximately 90% of simultaneous plasma concentrations. Concentrations in wound exudate exceeded those measured in plasma four hours after the dose, and elimination from the wound was slower than from plasma. AAG concentrations in plasma increased from a mean of 89 mg/dL intraoperatively to 134 mg/dL postoperatively. AAG was present in wound exudate in concentrations that were approximately 53% of those observed in plasma.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pharmacy Practice, University of Pittsburgh, PA 15261.
authors.forename: G P
authors.initials: GP
authors.lastname: Stoehr
authors.forename: V L
authors.initials: VL
authors.lastname: Yu
authors.forename: J T
authors.initials: JT
authors.lastname: Johnson
authors.forename: E J
authors.initials: EJ
authors.lastname: Antal
authors.forename: R J
authors.initials: RJ
authors.lastname: Townsend
authors.forename: R
authors.initials: R
authors.lastname: Wagner
mesh_terms: D000368:Aged; D002981:Clindamycin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011292:Premedication; D013530:Surgical Wound Infection / Q000517:prevention & control; D014018:Tissue Distribution
chemical_list: D002981:Clindamycin